Image Description (1 Formula)
Felodipine Tablet, Film Coated
Product Images NDC 51407-089
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 51407-089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
51407-087-01lb.jpg (51407 087 01lb)
NDC 51407-087-01 is a medication called Felodipine. This medication comes in the form of extended-release tablets, USP, with a strength of 2.5mg and is supplied in a bottle containing 100 tablets. Dosage information can be found in the package insert. Store the medication at room temperature between 20°-25°C (68°-77°F).*
51407-088-01lb.jpg (51407 088 01lb)
Product: FELODIPINE Tablets, USP 5mg - 100 tablets - Extended-Release. This medicine should be taken by swallowing it whole, NOT crushed or chewed. Dosage information is provided in the package insert. Store at temperatures between 20°C-28°C. Dispense in a tight and light-resistant container as indicated by the USP. Manufactured by Yung Shin Pharmaceutical Ind. Co., Ltd. in Tainan, Taiwan. Marketed and distributed by GEMS, Inc. in Camarillo, CA, USA.*
51407-089-01lb.jpg (51407 089 01lb)
Feoldipine is an extended-release medication available in 10mg tablets. The tablets should be swallowed, not chewed. The package insert should be consulted for dosage information. The manufacturer is Yung Shin Pharmaceutica Ind. Co., Ltd. and the product is packaged by GEMS, Inc. The ideal storage temperature is between 20-26°C (68-78°F).*
Table 1 (Table 1)
This is a table showing the mean reductions in blood pressure (in mmHg) with different doses of a medication over 8 and 4 weeks for two different studies. Placebo response has been subtracted from the values. The number of patients available for peak and trough measurements differs.*
Table 2 (Table 2)
This table shows the percentage of patients who experienced adverse events while taking Felodipine extended-release tablets as a monotherapy in controlled trials. The adverse events are categorized by body system, and the incidence of discontinuations is also shown. The patients were divided into four groups based on the different doses they received. Peripheral edema was the most common adverse event reported, followed by asthenia, palpitation, headache, and dizziness. Patients in titration studies may have been exposed to more than one dose level of Felodipine extended-release tablets.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
